Johnson & Johnson Strengthens Pharmaceutical Portfolio with Strategic Acquisitions in 2024

　　【Pharmaceutical Network Enterprise News] From a global perspective, large pharmaceutical companies choosing to acquire relevant projects and pipelines has already become a mature operational business model. On the basis of alignment with their own development strategies, large pharmaceutical companies are meticulously evaluating the pipeline assets and innovative value of Biotech firms before acquiring target companies to enhance their industrial layout. Notably, Johnson & Johnson has been making substantial acquisitions this year.
 

On May 28, Johnson & Johnson agreed to acquire Yellow Jersey Therapeutics, a subsidiary of Swiss pharmaceutical company Numab Therapeutics, for $1.25 billion, including the eczema candidate drug NM26. This bispecific antibody is currently entering Phase 2 clinical development for the treatment of atopic dermatitis (commonly known as eczema).
 

According to the agreement, Johnson & Johnson will obtain the rights to develop, manufacture, and commercialize NM26 for the treatment of atopic dermatitis and other targeted conditions. The transaction is expected to be completed in the second half of 2024.
 

It is reported that this is Johnson & Johnson's second bispecific antibody deal in May. On May 17, Johnson & Johnson announced that it had reached an agreement with Proteologix to acquire the biotechnology company Proteologix for $850 million in cash. The transaction is expected to be completed by mid-2024. Johnson & Johnson stated that this acquisition will strengthen the company’s dermatology product portfolio and provide an opportunity to meet significant demand in the atopic dermatitis (AD) field.
 

Industry insiders said that these two acquisition cases reflect Johnson & Johnson's strategy for multiple disease pathways of AD. In addition, according to the review, since this year, Johnson & Johnson has also completed several large-scale acquisitions.
 

On April 5, 2024, U.S. time, Johnson & Johnson (NYSE: JNJ) announced that it had agreed to acquire Shockwave Medical (Nasdaq: SWAV) for approximately $13.1 billion (approximately RMB 94.8 billion). Shockwave Medical is a manufacturer of intravascular lithotripsy (IVL) technology. Subject to the approval of Shockwave's shareholders and other conditions, the two companies expect the transaction to be completed by mid-2024. According to available information, Shockwave Medical focuses on developing products for the treatment of calcified cardiovascular diseases and is the company that launched the shockwave balloon catheter. After the completion of this transaction, Shockwave will operate as a business unit of Johnson & Johnson MedTech. Financially, it will belong to the company’s cardiovascular portfolio (formerly known as Interventional Solutions).
 

A relevant official from Johnson & Johnson Medical Technology stated that Shockwave Medical has brought a "truly unique opportunity." The company’s Intravascular Lithotripsy (IVL) technology for treating Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD), along with its robust product pipeline, is highly advanced. He believes this deal will strengthen the company's position in the medical technology field, particularly in the cardiovascular intervention sector. It is reported that in recent years, Johnson & Johnson has been actively acquiring companies in the cardiovascular field. For instance, in 2022, Johnson & Johnson acquired medical device manufacturer Abiomed for $16.6 billion.
 

In March 2024, Johnson & Johnson also announced that it had successfully completed the acquisition of Ambrx Biopharma. According to available information, Ambrx Biopharma is a clinical-stage biopharmaceutical company with a proprietary synthetic biotechnology platform used to design and develop next-generation ADCs. The acquisition was completed in an all-cash merger transaction, with a total equity value of approximately $2 billion (approximately RMB 14.3 billion at the time), and a net amount of $1.9 billion after deducting the estimated acquired cash. This transaction will be considered a corporate merger.
 

This acquisition presents a unique opportunity for Johnson & Johnson to design, develop, and commercialize targeted oncology therapeutics. Johnson & Johnson stated that Ambrx's proprietary ADC technology combines the advantages of highly specific targeted monoclonal antibodies with the safe linkage of potent chemotherapy drug payloads, enabling targeted and efficient elimination of cancer cells while avoiding common side effects typically associated with chemotherapy. "The Ambrx team has developed a promising pipeline of drug candidates and an ADC platform, which will provide a strong complement and strategic fit to our oncology innovation strategy."
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.